pDC Activation by TLR7/8 Ligand CL097 Compared to TLR7 Ligand IMQ or TLR9 Ligand CpG.

In this study, we treat pDCs with the TLR7 ligand IMQ, TLR7/8 ligands (CL097 and CL075), and three TLR9 ligands (different types of CpGs). The size of pDCs increased significantly after activation by TLR7, or TLR7/8 ligands. TLR7, TLR7/8, and TLR9 ligands similarly modulated cytokine release, as well as protein expression of pDC markers, costimulatory molecules, and cytotoxic molecules. Interestingly, TLR7/8 ligands, especially CL097, induced stronger responses. These results are relevant to the further study of the role and mechanism of pDC-induced antitumor effects and may aid in the development of a new strategy for future tumor immunotherapy. PMID: 31093508 [PubMed - in process]
Source: Journal of Immunology Research - Category: Allergy & Immunology Tags: J Immunol Res Source Type: research

Related Links:

Behind any landmark cure is years of medical research. But the old goal of research — to find a one-size-fits-all treatment for a disease, based on a set of standard protocols — must radically change to further and diversify advances in the field, experts argued at the TIME 100 Health Summit on Thursday. Sean Parker, an entrepreneur and founder of the Parker Institute for Cancer Immunotherapy, came to the complex world of biotech, life sciences and health care research as an outsider. (Parker co-founded Napster and was the first president of Facebook.) “It seemed like there was tremendous opportunity. The...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized HealthSummit19 Research Source Type: news
TIME held its first TIME 100 Health Summit on Thursday aiming to define — and shape — the future of health care. The Summit, which is an offshoot of the magazine’s annual TIME 100 list of influential people, featured scientists, politicians and entertainers, such as former President Bill Clinton, former Vice President Al Gore, NIH Director Dr. Francis Collins, actress Selma Blair, NBA commissioner Adam Silver, comedian Tig Notaro and former Planned Parenthood President Dr. Leana Wen. The day included a range of interviews, panels and performances. Here are the biggest moments from the Summit. Former Vice ...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Comedy HealthSummit19 onetime Source Type: news
AbstractThe interplay between the immune system and tumor progression is well recognized. However, current human breast cancer immunophenotyping studies are mostly focused on primary tumors with metastatic breast cancer lesions remaining largely understudied. To address this gap, we examined exome-capture RNA sequencing data from 50 primary breast tumors (PBTs) and their patient-matched metastatic tumors (METs) in brain, ovary, bone and gastrointestinal tract. We used gene expression signatures as surrogates for tumor infiltrating lymphocytes (TILs) and compared TIL patterns in PBTs and METs. Enrichment analysis and deconv...
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
Authors: Mkango SB, Shaban N, Mureithi E, Ngoma T Abstract A type of cancer which originates from the breast tissue is referred to as breast cancer. Globally, it is the most common cause of death in women. Treatments such as radiotherapy, chemotherapy, hormone therapy, immunotherapy, and gene therapy are the main strategies in the fight against breast cancer. The present study aims at investigating the effects of the combined radiotherapy and chemotherapy as a way to treat breast cancer, and different treatment approaches are incorporated into the model. Also, the model is fitted to data on patients with breast can...
Source: Computational and Mathematical Methods in Medicine - Category: Statistics Tags: Comput Math Methods Med Source Type: research
Triple negative breast cancer (TNBC) has the poorest prognosis of all breast cancer subtypes and is one of the most fatal diseases for women. Combining cytotoxic chemotherapy with immunotherapy has shown great...
Source: Journal of Nanobiotechnology - Category: Nanotechnology Authors: Tags: Research Source Type: research
AbstractPARP (poly(ADP-ribose) polymerase) inhibitors represent a novel class of anti-cancer therapy; they take advantage of synthetic lethality and induce cell death by exploiting a defect in DNA repair. This class of medication was initially evaluated in patients with BRCA-associated tumors, but efficacy was also demonstrated in other populations. Since 2014, four PARP inhibitors have been approved in various indications: olaparib, niraparib, and rucaparib in high-grade serous ovarian cancer, and olaparib and talazoparib in metastatic breast cancer. The exact indications and study populations vary slightly between the di...
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
When William Stewart Halsted described the radical mastectomy in 1894, it was thought that a cure for breast cancer lay in maximally invasive and often morbid surgery. Our understanding of breast cancer has changed immeasurably in the subsequent century in which innumerable preclinical and clinical studies have demonstrated that advanced breast cancer is a systemic disease that requires a multimodality approach that includes both local (surgery and radiation) and systemic therapies (chemotherapy, endocrine therapy, and/or immunotherapy).
Source: Surgery - Category: Surgery Authors: Source Type: research
Dr. Rebecca Dent, oncologist at the National Cancer Center, Singapore, discusses the rationale for immunotherapy in early-stage breast cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Purpose of review Highlight recent data in lung and breast cancer leptomeningeal disease and address clinical trials that are open for patients. Recent findings Patients with lung and breast cancer leptomeningeal disease have survival outcomes of less than 1 year, despite advances in treatment strategy. Efforts to develop liquid biopsy biomarkers of disease progression from cerebrospinal fluid and plasma are underway. There are over 10 clinical trials open for patients with leptomeningeal disease, half of which use immunotherapy. Summary Consortium-based, multicenter clinical trials for patients with leptomeningeal...
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: BRAIN AND NERVOUS SYSTEM: Edited by Marc Sanson Source Type: research
Ortiz-Lopez Germline mutations in BRCA1 and BRCA2 (BRCA1/2) genes are present in about 50% of cases of hereditary breast cancer. Proteins encoded by these genes are key players in DNA repair by homologous recombination (HR). Advances in next generation sequencing and gene panels for breast cancer testing have generated a large amount of data on gene variants implicated in hereditary breast cancer, particularly in genes such as PALB2, ATM, CHEK2, RAD51, MSH2, and BARD1. These genes are involved in DNA repair. Most of these variants have been reported for Caucasian, Jewish, and Asian population, with few reports for oth...
Source: Genes - Category: Genetics & Stem Cells Authors: Tags: Review Source Type: research
More News: Allergy & Immunology | Breast Cancer | Cancer | Cancer & Oncology | Immunotherapy | Study